Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy

Charlson syndrome index predicted survival in pancreatic cancer patients received immunotherapy

ObjectiveThe Charlson Comorbidity Index (CCI) is a widely utilized assessment tool for evaluating the mortality rate among patients with chronic diseases and tumors. Currently, there is a dearth of research investigating the correlation between CCI and survival rates in advanced pancreatic cancer pa...

Full description

Saved in:

Bibliographic Details
Main Authors:	Nan Zhang, Shiyun Chen, Yue Shi, Zhikuan Wang, Ru Jia, Guanghai Dai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Immunology
Subjects:	pancreatic cancer immune checkpoint inhibitors Charlson syndrome index survival immunotherapy combined therapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1487318/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Progress in immunotherapy for brain metastatic melanoma
by: Shicheng Zheng, et al.
Published: (2025-01-01)

Editorial: Advances in immunotherapy of hepatic-biliary-pancreatic cancers, volume II
by: Hu Jiaming, et al.
Published: (2025-01-01)

Anti-cancer immunotherapy-related cardiotoxicity: preventable and treatable
by: Wu Helena T., et al.
Published: (2025-01-01)

Immunotherapy in metastatic renal cell carcinoma: Insights from a Dutch nationwide cohort
by: Hilin Yildirim, et al.
Published: (2025-02-01)

Charlson comorbidity index has no incremental value for mortality risk prediction in nursing home residents with COVID-19 disease
by: Anum Zahra, et al.
Published: (2025-01-01)

Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
by: Konstantinos Lallas, et al.
Published: (2025-01-01)

Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial
by: Ying Cheng, et al.
Published: (2025-02-01)

Study on influencing factors of age-adjusted Charlson comorbidity index in patients with Alzheimer's disease based on machine learning model
by: Jian Ding, et al.
Published: (2025-01-01)

Editorial: Community series in adenosine pathways in cancer immunity and immunotherapy, volume II
by: Junjiang Fu, et al.
Published: (2025-01-01)

Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy
by: Xiangrui Zhang, et al.
Published: (2025-01-01)

Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives
by: Yunxiang Hu, et al.
Published: (2025-02-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

Comparative efficacy of programmed death ligand 1 inhibition and chemotherapy in advanced gastric or gastroesophageal junction cancer with combined positive score – a meta-analysis
by: Zakari Shaibu, et al.
Published: (2024-10-01)

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Advances in Immunotherapy and Targeted Therapy of Malignant Melanoma
by: Xue Wang, et al.
Published: (2025-01-01)

Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer
by: Beatriz Ramos, et al.
Published: (2025-02-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

Case report: Complete response of recurrent locally advanced basal cell carcinoma following addition of vismodegib to neoadjuvant cemiplimab therapy
by: Chalette Lambert-Swainston, et al.
Published: (2025-01-01)

Evaluation of patient immunocompetence for immune checkpoint inhibitor therapy using the psoas muscle index: a retrospective cohort study
by: Toshiaki Tsurui, et al.
Published: (2025-02-01)

The success of the tumor immunotherapy: neutrophils from bench to beside
by: Meng Zhu, et al.
Published: (2025-01-01)

Chemotherapy in synergy with innate immune agonists enhances T cell priming for checkpoint inhibitor treatment in pancreatic cancer
by: Nan Niu, et al.
Published: (2025-01-01)

Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation
by: Xinjun Lu, et al.
Published: (2024-11-01)

Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xinyu Zhang, et al.
Published: (2025-01-01)

It’s about TIME – Gal-9 as a potential immunotherapeutic target in pancreatic ductal adenocarcinoma
by: Christin Knickmeier, et al.
Published: (2025-01-01)

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)
by: Yingyi Li, et al.
Published: (2025-02-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Recent advances in immunotherapy targeting CETP proteins for atherosclerosis prevention
by: Wenhui Hu, et al.
Published: (2025-12-01)

Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases
by: Taoyuan M Beninato, et al.
Published: (2024-12-01)

Long term survival of advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: a case report
by: Xiaoli Wang, et al.
Published: (2025-02-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

The prognostic value of circulating tumor DNA in malignant melanoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Lei Liu, et al.
Published: (2025-01-01)

Neoadjuvant chemotherapy combined with antiangiogenic therapy and immune checkpoint inhibitors for the treatment of locally advanced gastric cancer: a real - world retrospective cohort study
by: Zhouwei Zhan, et al.
Published: (2025-02-01)

Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review
by: Gui-Lin Xie, et al.
Published: (2025-01-01)

Outcomes after Surgery for Malignant Pancreatic Neuroendocrine Tumors
by: Omar Hama Ghalib Azeez Hawramy, et al.
Published: (2019-08-01)

PARP inhibitors in the treatment of Pancreatic Cancer - A Review of literature
by: Jagoda Niewiadomska, et al.
Published: (2025-01-01)

Unfavorable Tumor Responses to Immunotherapy in the Liver: Lessons Learned from Clinical and Preclinical Studies
by: Li-Chun Lu, et al.
Published: (2023-04-01)

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy
by: Anqi Lin, et al.
Published: (2025-12-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)